IDO1 and metastatic neoplasm: In metastatic disease, Hamid et al. [79] have reported the improved outcome of ipilimumab therapy among patients with elevated tumor infiltrating lymphocyte counts (TIL) and elevated Treg and IDO levels at pretreatment biopsy.